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Abstract:  
Background & Aims: Relatives of individuals with Crohn's disease (CD) carry CD-
associated genetic variants and are often exposed to environmental factors that increase their 
risk for this disease. We aimed to estimate the utility of genotype, smoking status, family 
history, and other biomarkers can be used to calculate risk in asymptomatic first-degree 
relatives of patients with CD. 
Methods: We recruited 480 healthy first-degree relatives (full siblings, offspring or parents) 
of patients with CD through the Guy’s and St Thomas’ NHS Foundation Trust and from 
members of Crohn’s and Colitis, United Kingdom. DNA samples were genotyped using the 
Immunochip. We calculated a risk score for 454 participants, based on 72 genetic variants 
associated with CD, family history, and smoking history. Participants were assigned to 
highest and lowest risk score quartiles. We assessed pre-symptomatic inflammation by 
capsule endoscopy and measured 22 markers of inflammation in stool and serum samples 
(reference standard). Two machine-learning classifiers (elastic net and random forest) were 
used to assess the ability of the risk factors and biomarkers to identify participants with small 
intestinal inflammation in the same dataset. 
 
Results: The machine-learning classifiers identified participants with pre-symptomatic 
intestinal inflammation: elastic net (area under the curve, 0.80; 95% CI, 0.62–0.98) and 
random forest (area under the curve, 0.87; 95% CI, 0.75–1.00). The elastic net method 
identified 3 variables that can be used to calculate odds for intestinal inflammation: combined 
family history of CD (odds ratio, 1.31), genetic risk score (odds ratio, 1.14), and fecal level of 
calprotectin (odds ratio, 1.04). These same 3 variables were among the 5 factors associated 
with intestinal inflammation in the random forest model. 
 
Conclusion: Using machine learning classifiers, we found that genetic variants associated 
with CD, family history, and fecal level of calprotectin together identify individuals with pre-
symptomatic intestinal inflammation who are therefore at risk for CD. A tool for detecting 
people at risk for CD before they develop symptoms would help identify the individuals most 
likely to benefit from early intervention. 
 
KEY WORDS:  
What You Need to Know  
Background: Relatives of individuals with Crohn's disease (CD) carry CD-associated genetic 
variants and are often exposed to environmental factors that increase their risk for this 
disease. We investigated whether genotype, smoking status, family history, and other 
biomarkers can be used to calculate risk in asymptomatic first-degree relatives of patients 
with CD. 
 
Findings: Using machine learning classifiers, we found that genetic variants associated with 
CD, family history, and fecal level of calprotectin together identify individuals with pre-
symptomatic intestinal inflammation who are therefore at risk for CD. 
 
Implications for patient care: A tool for detecting people at risk for CD before they develop 
symptoms would help identify the individuals most likely to benefit from early intervention. 
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Introduction 
 
Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a 
chronic inflammatory condition of the gastrointestinal tract associated with significant morbidity. 
Family members of CD patients are at increased risk for developing the disease with estimates of 
sibling risk ranging from 15-42 times greater than the general population
1
. 
 
Although CD pathogenesis remains incompletely understood, the role of genetic risk factors is well 
established. Twin studies estimate that the heritability (proportion of trait variance explained by 
genetic factors), is 0.756. To date, there are over 240 genetic variants or single nucleotide 
polymorphisms (SNPs) robustly associated with IBD through genome-wide association studies 
(GWAS)
2
 which account for approximately half of the heritability estimate for CD
3
. A recent study of 
first-degree relatives (FDRs) of patients with IBD showed that they are enriched for IBD-associated 
risk loci
4
. 
 
Familial clustering of disease is likely the result of shared environmental factors, as well as genetic 
risk factors. The increasing incidence of the disease among populations with historically lower rates, 
and those migrating from regions with low incidence rates to regions with higher rates, is consistent 
with a substantial environmental risk component to CD
5
. Many lifestyle-related factors have been 
implicated, including stress, sedentary lifestyle, western diet, poor sleep, and tobacco use
6,7
. 
Smoking is the best-studied environmental risk factor with recent  estimates suggesting a nearly 
two-fold increase risk for CD
8
.  
 
Asymptomatic FDRs may display phenotypic features in common with CD patients including altered 
intestinal permeability, positive serological antimicrobial markers, disordered innate and acquired 
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immunity, faecal dysbiosis, and elevated faecal calprotectin (FC)
9
. Overt small intestinal (SI) 
inflammation has been described in FDRs who have undergone ileocolonoscopy
10
, intestinal 
ultrasound
11
and video capsule endoscopy (VCE)
12
.  
 
Evidence of increased risk factors for CD in FDRs raises the possibility of predicting those at risk of 
developing the disease
9
. We hypothesized that higher genetic risk in FDRs compared to healthy 
controls
4
, elevated FC levels
9
, and smoking, taken together could provide sufficient information to 
detect at-risk individuals before the development of overt symptoms. This has the potential to 
enable early interventions to alter or halt aberrant immune and inflammatory responses, and 
perhaps, ultimately, prevent disease.  In this study we aimed to assess the clinical utility of a disease 
risk model to predict the presence of SI inflammation as detected by VCE.  We applied two machine-
learning methods to risk factors including genetic variants, smoking status, family history of disease 
and 22 inflammatory biomarkers, and assessed the predictive ability of the derived models.  
 
Materials and Methods 
 
Participants 
We recruited 480 healthy FDRs (full siblings, offspring or parents) through CD patients attending the 
IBD service at Guy’s & St Thomas’ NHS Foundation Trust (GSTT) and from members of Crohn’s & 
Colitis UK (a charity supporting patients with IBD). CD diagnosis in the probands was confirmed by 
their gastroenterologist or general practitioner. FDRs provided information regarding family history 
of IBD, medical history (including gastrointestinal symptoms), smoking status, medications, allergies, 
primary care provider and ethnicity. In keeping with the population of the CD GWAS meta-analysis
13
, 
only FDRs of European ancestry were included. Further inclusion criteria were: ability to give written 
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informed consent, age 18-55 years, and absence of gastrointestinal symptoms. The exclusion criteria 
were: a previous diagnosis of IBD, irritable bowel syndrome, or other major co-morbidity, pregnancy, 
major bowel surgery, or the use of non-steroidal anti-inflammatory drugs in the 4 weeks prior to 
capsule endoscopy (low-dose aspirin excluded).  
 
DNA collection and genotyping  
Saliva sampling kits (Oragene™ DNA OG-500) were sent to 480 FDRs that met the inclusion criteria. 
DNA samples were genotyped on the Immunochip
14
 which included 72 known significant CD SNPs at 
the time of study design (Supplementary methods). Genotypes for these 72 variants were extracted 
for genetic risk profiling and underwent standard quality control (QC) in PLINK
13,15
 (Supplementary 
methods).  
 
Calculation of high and low risk groups 
We generated a combined CD risk score in 454 FDRs based on genotype (Table S1)
13
  and smoking 
status (current, ex, never-smoker)
16
 using the R package REGENT
17
. Summary results were obtained 
for 72 CD risk variants using odds ratios (OR) estimated from GWAS meta-analysis
13
 (Supplementary 
methods). Smoking status was recorded as "Current", "Ex", or "Never" smoked with "Never" smoked 
as the reference. Smoking risk was incorporated into the REGENT analysis using ORs from a large 
case-control study
16
. FDRs in the highest and lowest quartiles of the risk score were invited to 
undergo VCE and provide stool and blood samples for biomarker analysis.  
 
Video capsule endoscopy (VCE) 
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Capsule endoscopies were performed in the Endoscopy Unit at GSTT following written informed 
consent using MiroCam™ (Intromedic, Seoul, Korea) VCE system (Supplementary methods). Two 
validated scoring systems were used to quantify SI inflammation: the Lewis Score
18
 and the Capsule 
Endoscopy Crohn’s Disease Activity Index (CECDAI)
19
. SI transit time was defined as the passage from 
the first duodenal to the first caecal image, in minutes.  
 
Biomarker assays 
Stool samples were collected between 1-72 hours prior to the administration of laxatives for VCE 
and were stored at -80°C before faecal calprotectin (FC) extraction and ELISA analysis (Buhlmann EK-
CAL Calprotectin, Buhlmann Laboratories, Schönenbuch, Switzerland). Approximately 20ml of blood 
in serum separator tubes (BD Vacutainer® SST™, BD Diagnostics, Oxford, UK) was collected from 
participants when they attended for VCE. Samples were centrifuged at room temperature for 10 
minutes at 1300g. Sera were stored at -80°C prior to analysis for high-sensitivity C-reactive protein 
(hs-CRP), anti-saccharomyces cerevisiae antibodies (ASCA), and 18 additional cytokines, growth 
factors and cell adhesion molecules (Supplementary methods).  
 
Statistical analysis 
All statistical analyses were performed using R Project for Statistical Computing
20
. For the predictive 
modelling we used the R package caret
21
, and its dependencies glmnet
22
 and ranger
23
. 
 
Explanatory modelling: Logistic regression was used to model SI inflammation with dichotomized 
Lewis score from the VCE (<135 = normal/no inflammation, ≥135 = abnormal/intestinal 
inflammation).  Explanatory variables of age, gender, genetic risk, smoking, CD family burden 
(“single” or “multiple” members affected with CD), VCE transit time and biomarkers were modelled 
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using stepwise selection applying Akaike's information criterion (AIC) and the Bayesian information 
criterion (BIC), which seeks a more stringent model.  Further details are given in Supplementary 
methods.   
 
Predictive modelling: Machine learning was used to generate a predictive model to estimate the 
utility of the genetic, environmental and biomarker variables to identify individuals at high risk of SI 
inflammation. We divided the data into a training sample (2/3rds) for model building and a test 
sample (1/3rd) for evaluation of the model’s predictive performance and compared two machine 
learning techniques, Elastic Net and Random Forest (Supplementary methods). For each approach, 
20 repeats of 5-fold cross validation were used on the training data to optimise fit. The model was 
then applied to the test sample to attempt to classify FDRs with and without inflammation. 
Predictive performance was assessed with the area under the receiver-operator characteristic curve 
(AUC).  Further details are given in Supplementary methods.   
 
An updated SNP list: sensitivity test 
To update our SNP list in line with more recent GWAS studies 
24
 we performed a sensitivity test to 
compare the effect of using a larger set of risk SNPs with updated risk score (see Supplementary 
methods). 
 
Results 
 
Calculating the high and low risk quartiles 
The relative risk (RR) of CD in the 454 asymptomatic FDRs generated from 72 genetic risk markers 
and smoking status (Figure 1) ranged from 0.03–38.3 and was significantly higher than expected in 
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the general population (supplementary Figure S1) (p=0.013). Demographic information for each risk 
quartile is shown in supplementary Table S2. FDRs in the highest and lowest risk quartiles (n=228) 
were invited to participate in phase 2 of the study (Figure 1), of these 81 were unable to attend for 
varying reasons including travel and work commitments (Figure S2). The remaining 147 (64%) 
underwent VCE, 81 from the highest risk quartile and 66 from the lowest risk quartile (Table 1). For 
subsequent modelling, the risk score in the high and low risk quartiles was separated into a genetic 
score and smoking status.  
 
Fecal and serum biomarker analysis 
FC measurement was performed on 134 returned samples from FDRs in phase 2. Where adequate 
sample was provided, sera were analysed for 21 additional biomarkers resulting in complete 
biomarker data on 124 individuals (Figure S2). Six biomarkers had near zero variance among these  
individuals and were not analysed further (supplementary Table S3). A comparison of the 
demographics between those individuals with complete and incomplete data demonstrated no 
significant differences for age, gender or relationship to proband although some differences were 
observed for smoking status and CD family history (Table 1).   
 
Video capsule endoscopy findings 
All 147 FDRs in phase 2 underwent VCE and in 144 the caecum was reached (supplementary Figure 
S2). There was one capsule retention, managed conservatively with prokinetic agents. The most 
common abnormal finding was of small aphthous ulceration in the distal ileum. No strictures were 
identified. Marked inflammation typical of CD (>150 aphthous ulcers throughout the SI) was found in 
only one FDR, in the high-risk group. The majority (93%) of the lowest risk group had no SI 
inflammation (Lewis score <135) compared with 67% of the highest risk group (p=0.00037, Table 1). 
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In the high-risk group, 9% had moderate-severe inflammation (Lewis score ≥790) compared with 
none in the low risk group (p=0.016). Less than half of those with moderate-severe SI inflammation 
(45.6%) had a raised FC (>=50ug/g), which fell to 6% in those without SI inflammation (Figure S3). 
 
All 11 participants with moderate-severe small bowel inflammation were offered follow-up in the 
IBD clinic at GSTT to discuss ongoing surveillance and the need for treatment. Of these, 8 
participants attended for at least one visit. At the 3-year follow-up one of these had been diagnosed 
with and treated for CD. Five-year follow-up of the entire cohort will be completed in the next 12 
months.    
 
Characteristics of the highest and lowest risk quartiles 
Of the 147 FDRs who underwent VCE, 124 had complete data for all biomarkers and were included 
in all analyses (supplementary Table S4). Among these variables, smoking and Lewis score showed a 
significant difference by risk quartile (Table 1). The Lewis and CECDAI capsule scores were highly 
correlated (Pearson's r=0.89, 95% CI=0.85-0.92, p<0.01) and when each measure was dichotomized 
(Normal, Abnormal) only 3 samples were classified differently. For all modelling, we used the 
dichotomized Lewis score as our outcome, as this has previously been shown to correlate well with 
FC whereas the CECDAI did not
25
. 
 
Explanatory modelling 
SI inflammation (based on Lewis score) was modelled using all genetic, environmental and 
biomarker variables to explain the observed VCE data. Using stepwise selection and AIC we reduced 
the number of predictor variables to a best explanatory subset of 14 (R2=0.72). Stepwise selection 
using the more stringent BIC yielded 3 variables (R2=0.47) including FC, CD family history, and 
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genetic risk score (supplementary Table S5). Although regression modelling can quantify the 
variance in the outcome explained by the predictors, these classical statistical approaches do not 
account for correlation among predictors (Figure S4) and provide no indication of the predictive 
ability of the derived model. 
 
Predictive modelling 
Predictive models using elastic net and random forest were built on a training sample of 83 FDRs, 
then tested on the remaining sample of 41 FDRs. The predictive performance of both methods was 
assessed with the area under the receiver-operator characteristic (ROC) curve (Figure 2).  The 
random forest (AUC=0.87, 95% CI=0.75 – 1.00; Accuracy=0.73, 95% CI=0.57 – 0.86) performed 
slightly better than the elastic net (AUC=0.80, 95%CI=0.62 – 0.98; Accuracy=0.68, 95% CI=0.52 – 
0.82), correctly classifying an additional 2 test samples (1 normal/un-inflamed, 1 abnormal/inflamed) 
among the 41 unseen test samples (Table 2, Table S6). 
 
Genetic risk score improves predictive performance 
The elastic net model reduced the full set of predictor variables to the three most important 
variables: CD family history (OR=1.31), genetic risk score (OR=1.14), and FC (OR=1.04) 
(supplementary Table S7). Although it is not possible to assign p-values or confidence intervals to 
individual predictors in a cross-validated elastic net solution
26
, interestingly, these were the same 
predictors selected by stepwise BIC in the explanatory modelling (Table 3, supplementary Table S5). 
Genetic risk score was the second most important variable in the random forest model. Although it 
is possible to assign p-values to importance in a random forest, in order evaluate the contribution of 
genetic risk to both models in a comparable way, we built the two models with and without genetic 
risk score. In both models, excluding genetic risk score reduced predictive performance for SI 
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inflammation. An elastic net excluding genetic risk score yielded a two-variable model: FC (OR=1.09) 
and CD family history (OR=1.63) with significantly lower AUC (0.78, 95% CI: 0.55 – 1.00) compared to 
the original full elastic net model (AUC=0.80, 95% CI=0.62 – 0.98 (Mann-Whitney U test derived
27
)). 
Likewise, performance of a random forest model excluding genetic risk score was significantly lower 
(AUC=0.83, 95% CI: 0.67 – 0.99) than the original random forest model (AUC=0.87, 95% CI=0.75 – 
1.00). 
Updated SNP set and risk scores 
Using updated SNP risk data from Jostins et al 2012 we found that the original and updated risk 
scores and the updated and expanded risk scores were highly correlated (r = 0.952, Figure 3, r = 0.72 
Figure S5 respectively). Also, the risk of being in the highest risk quartile, given the presence of SI 
inflammation, was very similar under the  original SNP set and risk scores OR = 6.48 (95% CI: 2.08 - 
20.19), and the expanded SNP set and risk scores OR = 6.21 (95% CI: 1.28 - 30.18) (See 
Supplementary material for further details). 
 
 
Discussion 
 
We found that the combination of CD family history, genetic risk, and level of FC was a good 
predictor of SI inflammation in our cohort of FDRs. Both machine learning classifiers performed 
similarly, with significant prediction of SI inflammation, and both put CD family history, genetic risk 
and FC as top predictors, which increases confidence in the model’s utility. CD family history was the 
strongest predictor in the elastic net model and ranked 5th most important predictor in the random 
forest. By design, all our study participants had at least one relative with CD; we found that a 
stronger family history (≥2 relatives with CD) increased the risk for SI inflammation, agreeing with 
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previous studies
4
. However, the number of affected family members is a crude measure of familial 
risk. Ideally, total family size, structure, and age of affected individuals should also be incorporated
28
. 
 
We found that genetic risk score was a significant predictor of SI inflammation. The predictive 
accuracy of our elastic net classifiers with or without genotype were both within the 0.7–0.8 range 
generally considered to be acceptable discrimination
29
. Performance of the random forest models 
with or with genotype were both in the 0.8-0.9 range considered excellent discrimination. On 
inclusion of genetic risk in the model elastic net estimates showed a 2% and random forest a 4% 
increase in AUC, thus predicting an additional 2 and 4 cases respectively in every 100 randomly 
selected pairs. In computing the genetic risk score we used 72 CD-associated genetic variants known 
at the time of clinical assessment
13
, and the single best-understood lifestyle factor, smoking. Since 
then the number of genetic loci associated with IBD has risen to 240 
24,30,31
. To estimate the effect of 
updating risk variants, we used the set of CD associated SNPs identified in the Jostins et al (2012) 
GWAS meta-analysis for which we had available data, given that we had used the same genotyping 
array (Immunochip). We showed a high correlation (r2=0.952), between our original risk scores used 
to select FDRs for VCE and the updated risk scores based on this expanded more recent set of risk 
SNPs. Updating the genetic risk panel as more risk loci are discovered could increase the 
performance of the model further.  
 
We found that 35% of FDRs had an  elevated FC (≥50 μg/g), which has previously been observed in 
asymptomatic FDRs
12
. As FC is part of the diagnostic work-up for CD
10
, and increased levels predict 
relapse
32
, our findings of its predictive utility for SI inflammation suggest it is a promising biomarker 
for those at greatest risk for CD. However, we observed that a cut-off of ≥50 μg/g would include 
many false positives, whereas a threshold of >250 μg/g, which has been suggested as appropriate 
for screening asymptomatic individuals,
33
  resulted in a high false negative rate in our FDR cohort 
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(>80%, Figure S3). Therefore, our data demonstrates that FC alone has limited use in classifying 
asymptomatic individuals at greatest risk for developing CD, whereas our predictive model benefits 
from the full range of information contained in the biomarker in the context of all other predictors.  
 
Mild SI inflammation found at VCE has previously been reported at a rate of 24% of asymptomatic 
FDRs, but the subsequent development of CD was not determined
34
. A study of 38 FDRs who 
underwent ileocolonoscopy found mild endoscopic and histological inflammation in 26% and CD in 
13%. Those with mild inflammation underwent repeat ileocolonoscopy after a mean of 53 months 
without endoscopic or histological progression of inflammation
10
. In our study 26/124 (21%) FDRs 
had abnormal Lewis scores, which is broadly consistent with these data. However, it is not certain 
whether these features are predictive of future development of CD.  Long term follow-up of our FDR 
cohort may provide further information regarding risk of developing overt CD as opposed to 
asymptomatic SI inflammation.  
 
Although we used an unseen subset of samples to test the predictive performance of our model, this 
test sample was subject to the same design decisions as the training samples, as well as any study-
specific idiosyncrasies. Ultimately, our finding will require external validation by replication in an 
independent sample.  
 
A future replication study could benefit from the inclusion of an updated list of  IBD-associated SNPs 
(most IBD loci confer risk for both CD and UC
31
), and a more comprehensive picture of the 
environmental risk (i.e., in addition to smoking, medication, diet, stress, sleep, physical activity
9
). 
Finally, this study did not assess the gut microbiome, a likely predictor of risk for CD and potential 
target for intervention. The Genetic, Environmental and Microbiome (GEM) Project, currently 
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recruiting 5000 CD FDRs internationally, will hopefully bring further insights into pre-clinical CD with 
the combination of all of these factors
35
. 
In parallel with our increasing understanding of the specific genetic and environmental risk factors 
that combine to make an individual's immune system hostile to commensal gut flora, a clinically 
useful tool for detecting those at greatest risk for CD before the presentation of overt symptoms 
would prioritise patient screening and follow up. Early detection opens up the possibility for early 
intervention, additional targets for drug development, and disease prevention. Our study suggests 
that a CD prediction tool can be built from a small set of biomarkers, known genetic risk variants, 
and family history of CD. Inclusion of risk factors from the most recent findings will improve 
prediction accuracy. 
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Table 1. Distribution of demographics, relationship and Lewis score by risk quartile 
Table 2. Classification tables: cross-tabulations of observed (reference) and predicted outcome. 
Table 3. Relative predictor importance. 
 
Figure legends 
 
Figure 1. Difference in relative risk between the quartiles (see Methods  for explanation of 
calculation). n = 114 first quartile (lowest risk), 113 second quartile, 113 third quartile, 114 fourth 
quartile (highest risk).  
 
Figure 2. Classifier evaluation by ROC for test sample. Test sample performance was similar for both 
models: elastic net sensitivity=0.75, specificity=0.67; random forest sensitivity=0.88, specificity=0.70. 
ROC curve: True positive rate (or Sensitivity) = TP / (TP+FN); True negative rate (or 1-Specificity) = 1 - 
(TN / (TN+FP)). 
 
Figure 3. Correlation between the original risk score - which incorporates 69 SNPs and corresponding 
risks from Franke et al, 3 x NOD2 risk variants (Materials and Methods), and smoking - and the 
updated Jostins et al (2012) risk scores for the same set of SNPs/variants. 
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Table 1. Distribution of demographics, relationship and Lewis score by risk quartile 
 HIGHEST RISK QUARTILE LOWEST RISK QUARTILE  
 Incomplete data Complete data Difference Incomplete data Complete data Difference Difference between 
highest and lowest 
risk quartiles with 
complete data 
Number 47 67  57 57  n/a 
Relationship to proband   p = 0.03   p = 0.12 p = 0.90 
sibling 22 (47%) 26 (39%)  25 (43%) 23 (40%)   
offspring 24 (51%) 29 (43%)  29 (50%) 22 (39%)   
parent 1 (2%) 12 (18%)  4 (7%) 11 (19%)   
Gender   p = 0.39   p = 0.44 p = 0.94
 
female 27 (57%) 45 (67%)  32 (56%) 37 (65%)   
male 20 (43%) 22 (33%)  25 (43%) 20 (35%)   
Age   p = 0.18   p = 0.18 p = 0.94 
mean 34.8 37.4  34.7 37.5   
median 34.3 37.4  33.2 36.2   
Smoking status   *p = 7.0 x 10
-4
   p = 0.70 *p = 1.1 x 10
-6
 
current 29 (62%) 23 (34%)  3 (5%) 6 (11%)   
ex 16 (34%) 25 (37%)  8 (14%) 8 (14%) 
  
never 2 (4%) 19 (28%)  46 (80%) 43 (75%) 
  
CD family history   *p = 2.2 x 10
-9
   *p = 2.8 x 10
-3
 p = 0.78 
single 15 (32%) 59 (88%)  38 (67%) 52 (91%)   
multiple 32 (68%) 8 (12%)  19 (33%) 5 (9%)   
Lewis score   n/a   n/a *p = 3.7 x 10
-4
 
Normal (<135) n/a 45 (67%)  n/a 53 (93%)   
Abnormal (≥135) n/a 22 (33%)  n/a 4 (7%)   
Incomplete data = subset of the respective risk quartile with missing VCE or biomarker data; Complete data = subset of the respective risk quartile with complete data on all measures; 
Difference = test of significant differences within (subsample with incomplete data vs subsample with complete data) and between (subsample with complete data: highest vs lowest) risk 
quartiles. Percentages are column percentages within each subheading. p-values relate to a test for equality of proportions, a t-test of mean differences, a Pearson's chi-squared test, or a 
Fisher's exact test as appropriate. * = significant after Bonferroni multiple test correction (0.05 / 16) 
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Table 2. Classification tables: cross-tabulations of observed (reference) and predicted outcome  
 
 
 Elastic net   Random forest 
  Reference    Reference 
  Normal Abnormal    Normal Abnormal 
Prediction 
Normal 22 2  
Prediction 
Normal 23 1 
Abnormal 11 6  Abnormal 10 7 
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Table 3. Relative predictor importance 
 Elastic net  Random forest 
Rank Predictor Importance  Predictor Importance 
1 CD family history 0.27  faecal calprotectin 0.0967 
2 genetic risk score 0.13  genetic risk score 0.0264 
3 faecal calprotectin 0.04  hs-CRP 0.0151 
4    IL6 0.0043 
5    CD family history 0.0023 
 
Note: Only top 5 predictors shown for the random forest. Importance is an indicator of a 
particular variable's contribution to model performance. The random forest importance is 
the mean decrease in accuracy given by the difference in error rate after permuting the 
particular variable, averaged over all trees. The elastic net importance is the absolute value 
of the regression coefficient t-statistic. 
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SUPPLEMENTARY MATERIAL: 
 
Predictors of elevated gut inflammation in asymptomatic first-degree relatives of patients with 
Crohn's disease 
 
*Kirstin M. Taylor, *Ken B. Hanscombe, *Natalie J. Prescott, Raquel Iniesta, Matthew Traylor, 
Nicola S. Taylor, Steven Fong, Nicholas Powell, Peter M. Irving, Simon H. Anderson, Christopher G. 
Mathew, Cathryn M. Lewis, Jeremy D. Sanderson 
 
* Joint first authors 
 
1. Supplementary Materials and Methods 
SNP genotyping 
DNA samples were genotyped on the Immunochip, a custom Illumina Infinium array containing 
196,524 SNPs and small insertion/deletions selected mainly from GWAS analysis of 12 immune-
mediated diseases
1
. The immunochip included 70 out of the 71  known significant CD SNPs based 
on genome wide association studies (GWAS) at the time of study design (rs736289 was not 
present on Immunochip)
2
. The Immunochip also included the three major CD-risk variants in 
nucleotide oligomerisation domain 2 gene (NOD2) rs2066844 (p.R702W), rs2066845 (p.G908R) 
and rs2066847 (p.L1007insC) and these were used in preference to the NOD2 tagging SNP 
(rs2076756) from Franke et al due to their well-established role in disease, bringing the total 
number of SNPs to 72. The three NOD2 risk variants were combined to model the inflated risk of 
NOD2 risk-variant homozygotes and compound heterozygotes as previously described
3
. 
SNPs with >3% missing genotype data and Hardy-Weinberg equilibrium outliers (p ≤ 1 x 10-4) were 
excluded. Individuals missing >3% of SNPs or with gender inconsistency were excluded. Population 
structure was assessed by principal components analysis in PLINK as previously described
4
, derived 
from HapMap 3 CEU population - Utah residents with Northern and Western European ancestry 
from the CEPH (Centre d’Etude du Polymophisme Humain). No outliers were identified.  
In total, 454 FDRs were successfully genotyped (61% female; median age 34, range 18-55; 40% 
were siblings, 46% offspring, 14% parents of probands; 44% were current or ex-smokers). 
 
Calculation of risk 
Risk modeling was performed within the R package, REGENT, incorporating published gene-
environment risk factor and disease statistics to categorize risk using a confidence interval (CI)-
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based approach within a simulated population
5,6
. Genetic risk factors (allelic odds ratios (ORs), 
allele frequencies and sample sizes) were determined from the first genome-wide meta-analysis in 
Crohn’s disease
7
 (See supplementary Table S1). The risk for NOD2 variants was more complicated 
due to the enhanced risk of homozygotes and compound heterozygotes. Extensive case-control 
data for NOD2 from our previously published studies
8,9
 was modeled using logistic regression in R 
to assess the model that provided the best fit in REGENT – simply counting the numbers of 
mutations proved best. Environmental risk factors required ORs, standard errors and the 
proportion of the population exposed to the risk factor, based on a large case-control study
3
. The 
first stage of REGENT involved simulation of a population-distribution of disease risk using a 
multiplicative model. Confidence intervals were used to classify the risk profiles into four 
categories: reduced, average, elevated and high-risk. The second stage of REGENT applied this 
simulated model to individual level data. This gave a disease risk in relation to the general 
population.  
 
An updated SNP list: Sensitivity testing 
The Immunochip employed here for genotyping was also used for a major IBD GWAS meta-
analysis that was published after the commencement of our study (Jostins et al, 201224). This 
described a total of 163 loci for IBD, which included nearly 70 new loci for CD (total 140 CD loci), 
all with updated risks based on a larger patient population. To investigate how these updated risk 
values affected our original model we performed a sensitivity test. We compared the distribution 
of normal versus abnormal inflammation across highest and lowest risk quartiles for our original 
risk score based on 69 SNPs using effect sizes from Franke et al 2010, (including NOD2 and 
smoking risk) with an updated risk score including the same 69 SNPs but using the effect sizes 
from Jostins et al., 2012. Then we compared the updated risk score to an expanded risk score 
including 134 out of 140 CD associated SNPs that passed QC in our data using effect sizes from 
Jostins et al., 2012. Where a GWAS identified variant was not available on the Immunochip, we 
used the reported Immunochip tag SNP24. For each individual, a genetic risk score was calculated 
as the weighted sum of the number of risk alleles using the log of the odds ratios. For tagging 
SNPs, the log(OR) was scaled down by the linkage disequilibrium between the GWAS-identified 
SNP and the Immunochip tag. As previously, we included the combined (homozygous and 
compound heterozygous) risk of the NOD2 variants and smoking in the updated and expanded risk 
SNP scores. 
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We found that the original and updated risk scores and the updated and expanded risk scores 
were highly correlated (r = 0.952, Figure 3, r = 0.72 Figure S5 respectively). Also, whilst we were 
unable to go back and re-select our highest and lowest risk quartiles from the FDR group for VCE, 
we calculated that the proportion of individuals in the highest risk quartile that had SI 
inflammation on VCE were comparable when using the original risk score (33%), the updated risk 
score (33%), and the expanded risk score (29%). The risk of being in the highest quartile, given the 
presence of SI inflammation, was found to be very similar under the two different risk models: the 
original risk score OR = 6.48 (95% CI: 2.08 - 20.19), the expanded risk score OR = 6.21 (95% CI: 1.28 
- 30.18). 
 
Biomarkers 
Approximately 20ml of blood in serum separator tubes (BD Vacutainer® SST™, BD Diagnostics, 
Oxford, UK) was collected from participants when they attended for capsule endoscopy. Samples 
were spun at room temperature for 10 minutes at 1300 relative centrifugal force (2500 rotations 
per minute) as per the manufacturer’s instructions. Aliquots of 1-2ml of serum were frozen at -
80°C. Serum was analysed for high-sensitivty C-reactive protein (hs-CRP) using the CardioPhase 
assay, Siemen’s Healthcare Diagnostics, Erlangen, Germany). Serum anti-saccharomyces cerevisiae 
antibodies (ASCA) were measured using the QUANTA Lite ASCA IgA and IgG ELISA assays (Inova 
Diagnostics, San Diego, California, USA). Serum cytokines and growth factors were analysed using 
the Randox Cytokine Chip Array Custom X, and adhesion molecules using the Randox Adhesion 
Molecules Array (both Randox Laboratories, Crumlin, Co Antrim, UK). Stool samples were collected 
before the administration of laxatives for VCE and were frozen at -80°C before faecal calprotectin 
(FC) extraction and ELISA analysis (Buhlmann EK-CAL Calprotectin, Buhlmann Laboratories, 
Schönenbuch, Switzerland). Adequate faecal specimens for calprotectin measurement were 
returned from 134 FDRs. Mean FC levels were similar in both risk groups (86 μg/g in high vs 90 
μg/g in low risk group, p=0.92) but were higher in those with moderate-severe small intestinal 
inflammation (186 μg/g) vs normal-mild inflammation (33 μg/g) p=0.03. 
 
Video capsule endoscopy 
The capsule endoscopies were performed in the Endoscopy Department of St Thomas’ Hospital 
following written informed consent. The MiroCam™ (Intromedic, Seoul, Korea) system was used 
for all capsule endoscopies. The MiroCam™ capsule (measuring 11 mm × 24 mm) was swallowed 
with water containing simethicone 40mg. Study participants were asked to avoid non-steroidal 
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anti-inflammatory drugs (NSAIDs) in the 3 months prior to capsule endoscopy. To improve 
diagnostic yield, two days before capsule endoscopy, FDRs began a low fibre diet, and the 
following day they commenced a clear liquid diet, followed by an overnight fast. A laxative, Picolax 
(Ferring, West Drayton, UK), containing sodium picosulphate and magnesium citrate, was taken in 
two doses the day before the procedure. Images were analyzed using a dual reading frame at a 
maximum speed of 24 frames per second. Each recording was read by two independent observers, 
fully trained in VCE, and blinded to each other and the risk status of the subject. Where there was 
a discrepancy in the findings, a third observer adjudicated. 
 
2. Explanatory modelling 
 
After removal of near-zero variance predictors (ASCA IgG, ASCA IgA, IL10, IL1a, IL4, INFy), we 
performed stepwise selection using the R package MASS with step direction = "both". Near zero 
variance evaluation is described below. We first fitted multivariate logistic regression models with 
dichotomized Lewis score (<135 = Normal i.e. without intestinal inflammation, ≥135 = Abnormal, 
i.e. with intestinal inflammation) as response variable, and age, sex, genetic risk score, smoking 
status, CD family history, VCE capsule transit time and the biomarkers as explanatory variables.  
FDRs by definition have one CD-affected relative. However, some participants had more than one 
affected family member. We included this additional family burden in our predictive modelling. 
Therefore, we defined the extent of CD family history as having “single” or “multiple” members 
affected with CD. Applying generalised linear regression models to a dataset with a large number 
of predictor variables relative to the number of samples is not optimal for several reasons 
including over-fitting (explaining noise as well as signal in the sample), multi-collinearity 
(correlation and potential redundancy among predictors), and low interpretability28. We used 
stepwise model selection to address this overfitting, multicollinearity, and model complexity. At 
each step in the iterative selection procedure, a variable is considered for addition to (or 
subtraction from) the current set of explanatory variables based on a model comparison criterion. 
We compared two criteria: Akaike's information criterion (AIC) and the Bayesian information 
criterion (BIC). However, this approach does not eliminate the problems of overfitting, 
multicollinearity, and model complexity, especially with a small sample and large number of 
measured variables. In addition, explanatory models can quantify the relationship between 
predictors and outcome in the particular sample collected (e.g. regression coefficients, and total 
variance explained), but they give no measure of the predictive performance of the putative 
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predictors in unseen cases. Given that the ultimate aim of the study was to estimate the utility of 
the genetic, environmental and biomarker variables to identify high risk individuals, we went on to 
derive a series of predictive models. Machine learning is specifically designed to deal with the 
large number of variables relative to sample size problem, and includes techniques to address the 
low events-per-variable ratio (small number of cases). Supplementary Table S5 shows the results 
of both Akaike information criterion (AIC) and the Bayesian information criterion (BIC) best 
explanatory selection. 
 
3. Predictive modelling 
 
Our goal was to develop a predictive model for SI inflammation, achieving a balance between 
interpretability (by reducing the number of predictor variables) and predictive ability. Thus we 
used machine learning, which has techniques for variable subset selection and estimation of how 
well a given model will perform at predicting future data29. Machine learning finds structure in 
data and addresses over-fitting when there are a large number of predictors. More generally, it is 
a set of techniques that improve performance on a specified task (e.g. classifying 
absence/presence of inflammation) with experience (exposure to data). We divided the data into 
a training sample (2/3) for model building and a test sample (1/3) for evaluation of model 
predictive performance and compared two machine learning techniques: 
 
Elastic net. The elastic net is an extension of the basic regression framework that allows selection 
of the most important subset of predictors. It mixes a ridge penalty (which shrinks the coefficients 
of correlated predictors towards each other) and a LASSO penalty (which selects one among a 
group of correlated predictors and shrinks the coefficients of the others to zero) to perform 
variable selection28. We used 20 repeats of 5-fold cross validation to estimate model parameters 
(penalty mixing factor (α) and penalty strength (λ)) that optimised the model's prediction 
performance, i.e., its ability to correctly classify individuals with and without inflammation. We 
measured prediction performance with the area under that receiver-operator characteristic curve 
(AUC: a plot of the true positive rate against the false positive rate for different cut-offs of the 
model estimated probability of being Abnormal) and accuracy (the fraction of test sample 
predictions that are true). The absolute value of the t-statistic for each parameter in the model is 
used to judge relative variable importance. 
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Random forest. A random forest is a collection of classification or regression trees. A tree is a 
series of splitting rules. At each split in a particular tree, from a random subset of predictors a 
single predictor is chosen that produces branches with the best split of Normal and Abnormal 
samples. Each resulting branch is then split until it ends in a "leaf" containing only (or mainly) 
Normal or Abnormal training samples. A test sample is then pass through each tree, and is 
assigned the (majority) class of the leaf on which it lands. Every tree in the forest produces a 
prediction and these predictions are combined to give a single consensus prediction for the 
individual28 29. We used 20 repeats of 5-fold cross validation on the training data to select the 
optimum number of randomly selected predictors (mtry) that maximized the AUC. Overall variable 
importance was determined by permuting predictors one at a time and measuring the mean 
decrease in accuracy averaged over all trees. 
 
Machine learning considerations 
 
Cross-validation 
In n-fold cross validation, the sample is randomly partitioned into 5 subsamples. For i = {1, 2, …, n}, 
the ith subsample is left out and the model is fitted (or estimated) on the n-1 remaining 
subsamples. The derived model is then evaluated on the ith left out subsample. The model 
evaluation metric (e.g. AUC) is then averaged across all i iterations. This was repeated over a range 
of values of α and λ in order to find the combination of penalty mixing and strength that produces 
the best elastic net predictive performance. Similarly, for the random forest the cross-validation 
was repeated over a range of values for mtry to find the optimal number of randomly selected 
variables to search among at each branching node. As the folds are randomly selected by design, 
we repeated the entire procedure 20 times to achieve a stable solution for both predictive 
models.  
 
Near zero variance predictors 
If most individuals in a dataset have a single unique value for a particular variable (i.e., a "near-
zero variance predictor"), including this variable in regression modelling can cause the model to 
become unstable or have undue influence on the model (see supplementary materials for more 
detail). If all individuals have the same value, the variable has zero variance and provides no useful 
information for model building. Near-zero variance is judged on two criteria: few unique values 
relative to the number of samples, and the ratio of the count of the most common value to the 
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count of the second most frequent value. We used caret::nearZeroVar options freqCut = 90/10 for 
ratio of most common variable value to second most common variable value and uniqueCut = 20 
for percentage of distinct values, to determine near-zero variance predictors. Effectively, a 
variable was dropped if its mode was 9 times more common than the next most frequent value 
and if less than 20% of the sample had a unique value. 
 
Importance 
Variable importance ranks the contribution of variables to a predictive model. The variable 
importance measure used for the elastic net is the absolute value of the t-statistic for each 
predictor in the underlying generalized linear model run on the training data. For the random 
forest, a predictor variable's importance is determined by the decrease in out-of-bag accuracy 
(averaged over all trees) after permuting the variable. The out-of-bag observations are the 
observations in the cross-validation fold used to evaluate model performance, during training. We 
used ranger::ranger option importance = "permutation" to calculate random forest predictor 
variable importance by permutation. 
 
Test-train sample split 
After performing data cleaning, including checks for near zero variance within and 
multicollinearity between predictors, we partitioned the data into training and test samples. We 
used 2/3 of participants in the training sample to tune model parameters and measure variable 
importance. In the remaining 1/3 we evaluated the predictive performance of each model.  Using 
caret::createDataPartition, we preserved the Normal-Abnormal ratio (class distribution) in the 
training and test samples. We pre-processed the training data (centred and scaled) and applied 
the training data location and scale to the test data before evaluation. 
 
Class imbalance 
For the elastic net, imbalance in the training sample was addressed using a weighting: (Normal, 
Abnormal)  (Normal, Abnormal * (Normal count/ Abnormal count)). This is a standard approach 
to class imbalance in logistic regression. For the random forest, we used the caret::trainControl 
option sampling = "down" to down-sample the majority class (Normal) to better match the rarer 
class (Abnormals). As the random forest is an ensemble method (results are combined across trees 
to generate a single prediction), down-sampling does not result in loss of information. If sufficient 
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trees are generated, all samples will be included. We generated a random forest with 2000 
classification trees. 
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Table S1. Genetic risk input file for REGENT  
No SNP MAF RR_het RR_hom Gene Ncase Ncontrol 
1 imm_1_7801650 0.19 1.05 1.1 VAMP3 6333 15056 
2 imm_1_67478546 0.068 0.38 0.14 IL23R 6333 15056 
3 imm_1_114179091 0.093 0.79 0.63 PTPN22 6333 15056 
4 imm_1_153496755 0.25 1.13 1.28 SCAMP3, MUC1 6333 15056 
5 rs4656940 0.199 0.87 0.76 CD244, ITLN1 6333 15056 
6 imm_1_171120083 0.246 1.22 1.49 TNFSF18 6333 15056 
7 imm_1_195994265 0.302 1.04 1.08 DENND1B 6333 15056 
8 imm_1_199144185 0.274 0.88 0.77 C1orf106 6333 15056 
9 imm_1_205006527 0.157 1.12 1.25 IL10, IL19 6333 15056 
10 1kg_2_25345971 0.326 1.06 1.12 DNMT3A 6333 15056 
11 rs780094 0.418 1.15 1.32 GCKR 6333 15056 
12 1kg_2_43660422 0.129 1.14 1.3 THADA 6333 15056 
13 imm_2_61077763 0.42 1.14 1.3 C2orf74, REL 6333 15056 
14 imm_2_102420881 0.231 1.19 1.42 IL18RAP 6333 15056 
15 rs6738825 0.473 1.06 1.12 PLCL1 6333 15056 
16 imm_2_230825118 0.187 1.12 1.25 SP140 6333 15056 
17 imm_2_233849156 0.471 0.75 0.56 ATG16L1 6333 15056 
18 rs13073817 0.322 1.08 1.17 0 6333 15056 
19 imm_3_49696536 0.297 1.22 1.49 MST1 6333 15056 
20 imm_5_40446341 0.394 0.75 0.57 PTGER4 6333 15056 
21 1kg_5_72586890 0.4 0.89 0.8 0 6333 15056 
22 imm_5_96270394 0.409 1.05 1.1 ERAP2, LRAP 6333 15056 
23 imm_5_131812292 0.422 1.23 1.51 SLC22A4 6333 15056 
24 imm_5_141459249 0.204 0.94 0.89 NDFIP1 6333 15056 
25 imm_5_150250613 0.088 1.37 1.88 IRGM 6333 15056 
26 imm_5_158719963 0.332 1.18 1.39 IL12B 6333 15056 
27 1kg_5_173212448 0.429 0.93 0.86 CPEB4 6333 15056 
28 rs17309827 0.361 0.91 0.83 0 6333 15056 
29 imm_6_20836710 0.216 0.85 0.73 CDKAL1 6333 15056 
30 rs1799964 0.209 1.19 1.42 LTA 6333 15056 
31 imm_6_91029880 0.342 0.93 0.87 BACH2 6333 15056 
32 imm_6_106541962 0.301 1.13 1.28 PRDM1 6333 15056 
33 imm_6_159410424 0.393 1.1 1.21 TAGAP 6333 15056 
34 imm_6_167326623 0.478 0.85 0.73 CCR6 6333 15056 
35 imm_7_50275007 0.31 0.88 0.77 IKZF1 6333 15056 
36 ccc-8-126606752-G-A 0.391 0.85 0.73 0 6333 15056 
37 rs6651252 0.135 0.81 0.66 0 6333 15056 
38 imm_9_4971602 0.349 1.18 1.39 JAK2 6333 15056 
39 imm_9_116592706 0.318 0.83 0.68 TNFSF15 6333 15056 
40 imm_9_138386317 0.411 1.18 1.39 CARD9 6333 15056 
41 imm_10_6142018 0.148 0.9 0.81 IL2RA 6333 15056 
42 imm_10_35575701 0.315 1.15 1.32 CREM 6333 15056 
43 1kg_10_59583157 0.226 0.84 0.71 UBE2D1 6333 15056 
44 imm_10_64115570 0.462 0.81 0.66 ZNF365 6333 15056 
45 imm_10_80730323 0.331 0.84 0.71 ZMIZ1 6333 15056 
46 imm_10_101274227 0.492 1.22 1.49 NKX2-3 6333 15056 
47 rs102275 0.341 1.08 1.17 FADS1 6333 15056 
48 rs694739 0.374 0.91 0.83 PRDX5 6333 15056 
49 rs7927997 0.389 1.17 1.37 C11orf30 6333 15056 
50 imm_12_39078567 0.025 1.74 3.03 MUC19, LRRK2 6333 15056 
51 1kg_13_41950880 0.346 1.1 1.21 TNFSF11 6333 15056 
52 imm_13_43355925 0.245 1.17 1.37 C13orf31 6333 15056 
53 imm_14_68279952 0.416 0.93 0.87 ZFP36L1 6333 15056 
54 1kg_14_87542348 0.119 1.23 1.51 GALC 6333 15056 
55 imm_15_65229650 0.233 1.12 1.25 SMAD3 6333 15056 
56 imm_16_28398018 0.386 1.07 1.14 IL27 6333 15056 
57 NOD2 (combined rs2066844, rs2066845 and rs2066847) 0.087 2.05 14.92 NOD2 15797 22548 
58 1kg_17_29617778 0.277 0.83 0.69 CCL2, CCL7 6333 15056 
59 imm_17_35294289 0.458 1.14 1.3 GSMDL 6333 15056 
60 imm_17_37826319 0.244 0.87 0.76 MLX 6333 15056 
61 imm_18_12799340 0.153 1.25 1.56 PTPN2 6333 15056 
62 1kg_19_1075835 0.247 1.16 1.35 GPX4 6333 15056 
63 rs12720356 0.084 1.12 1.25 TYK2 6333 15056 
64 imm_19_53906086 0.487 1.07 1.14 FUT2 6333 15056 
65 rs4809330 0.291 0.89 0.8 RTEL1 6333 15056 
66 imm_21_15734423 0.421 0.86 0.74 0 6333 15056 
67 imm_21_44439451 0.391 1.18 1.39 ICOSLG 6333 15056 
68 imm_22_20258597 0.203 1.1 1.21 YDJC 6333 15056 
69 imm_22_28922487 0.471 1.08 1.17 MTMR3 6333 15056 
70 imm_22_37989719 0.17 0.81 0.66 MAP3K7IP1 6333 15056 
 (SNP – single nucleotide polymorphism, MAF – minor allele frequency, RR_het – relative risk heterozygous for risk allele, 
RR_hom – relative risk homozygous for risk allele; Ncase – number of cases; Ncontrol – number of controls) 
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Table S2. Distribution of demographics, relationship and CD risk score by risk quartile for entire 
genotyped cohort 
 
 
Highest risk 
quartile 
Third risk 
quartile 
Second risk 
quartile 
Lowest risk 
quartile 
N =454 114 113 113 114 
Relationship to 
proband  
  
 
    sibling 48 (42%) 40 (35%) 46 (41%) 48 (42%) 
    offspring 53 (47%) 54 (48%) 50 (44%) 51 (45%) 
    parent 13 (11%) 19 (17%) 17 (15%) 15 (13%) 
Sex     
    female 72 (63%) 71 (63%) 66 (58%) 69 (61%) 
    male 42 (37%) 42 (37%) 47 (42%) 45 (39%) 
Age     
    mean 35.7 37.9 36.5 35.5 
    median 36.5 39 35 33 
 
    
Smoking status     
    current 52 (46%) 19 (17%) 5 (4%) 9 (8%) 
    ex 41 (36%) 27 (24%) 30 (27%) 16 (14%) 
    never 21 (18%) 67 (59%) 78 (69%) 89 (78%) 
CD family history     
    single 74 (65%) 75 (66%) 91 (81%) 90 (79%) 
    multiple 40 (35%) 38 (34%) 22 (19%) 24 (21%) 
 
 
Table S3. Biomarker descriptive statistics for 124 individuals with complete data and variance > 0 
Biomarker Description Mean (SD) / 
Count 
Median Range 
VCAM Vascular cell adhesion 
molecule (μg/g) 
573.44 (140.77) 559.69 38.49–1034.17 
ICAM Intercellular adhesion 
molecule (μg/L) 
239.26 (53.04) 232.26 33.54–390.27 
ESEL E-selectin (μg/L) 14.35 (4.97) 13.07 5.29–26.26 
PSEL P-selectin (μg/L) 277.70 (135.40) 231.54 134.21–729.24 
LSEL L-selectin (μg/L) 1872.42 (306.43) 1851.77 1242.69–2809.83 
*ASCA IgG Saccharomyces 
cerevisiae antibodies 
Immunoglobulin G  
Negative: 112, 
Equivocal: 4, 
Positive: 8 
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*ASCA IgA Saccharomyces 
cerevisiae antibodies 
Immunoglobulin A 
Negative: 113, 
Equivocal: 1, 
Positive: 10 
  
IL2 Interleukin 2 (ng/L) 1.17 (0.81) 0.90 0.90–6.07 
*IL4 Interleukin 4 (ng/L) 2.13 (0.10) 2.12 2.12–3.18 
IL6 Interleukin 6 (ng/L) 0.96 (1.28) 0.58 0.18–8.59 
IL8 Interleukin 8 (ng/L) 63.87 (130.17) 4.64 0.80–415.00 
*IL10 Interleukin 10 (ng/L) 0.49 (0.41) 0.37 0.37–3.75 
*IL1a Interleukin 1 alpha 
(ng/L) 
0.26 (0.22) 0.19 0.19–2.18 
IL1b Interleukin 1 beta 
(ng/L) 
1.18 (2.84) 0.67 0.26–31.09 
IL1RA Interleukin-1 receptor 
antagonist (ng/L) 
321.47 (335.95) 194.64 24.30–1657.37 
FC Faecal calprotectin 
(μg/g) 
68.58 (112.15) 36.25 10.00–866.50 
VEGF Vascular endothelial 
growth factor (pg/ml) 
60.19 (46.44) 47.50 8.57–283.08 
EGF Endothelial growth 
factor (ng/L) 
56.69 (39.01) 49.52 2.72–228.15 
*INFy Interferon gamma 
(ng/L) 
0.45 (0.09) 0.44 0.44–1.20 
TNFa Tumor necrosis factor 
alpha (ng/L) 
0.78 (0.25) 0.64 0.59–1.48 
MCP1 Monocyte 
chemoattractant 
protein 1 (ng/L) 
92.92 (95.69) 72.11 4.21–646.00 
hs-CRP Highly sensitive C-
reactive protein (mg/L) 
2.53 (3.41) 1.30 0.10–18.30 
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Table S4. Descriptive statistics for 124 individuals with complete data (67 high RR, 57 low RR) by Lewis score (0 = 
Normal, >0 = Abnormal) 
 
 
Normal 
      Lewis     Sex        Smoking         ASCAIgG         ASCAIgA   
 Normal : 98    F:67    Never  :50    Negative :91    Negative :90   
 Abnormal: 0    M:31    Current:21    Equivocal: 2    Equivocal: 1   
                        Ex     :27    Positive : 5    Positive : 7   
 
Abnormal 
      Lewis     Sex        Smoking         ASCAIgG         ASCAIgA   
 Normal  : 0    F:15    Never  :12    Negative :21    Negative :23   
 Abnormal:26    M:11    Current: 8    Equivocal: 2    Equivocal: 0   
                        Ex     : 6     Positive : 3    Positive : 3 
 
 
Normal 
mean sd median min max range skew kurtosis 
Age 38.08 10.46 37.55 19.5 56.7 37.2 0.09 -1.16 
Genetic Risk Score 0.66 1.02 0.47 -2.26 2.93 5.19 -0.24 -0.34 
Number CDFDR 1.06 0.28 1 1 3 2 4.89 25.41 
VCAM1 561.49 137.96 559.69 38.49 987.02 948.53 0.17 2.05 
ICAM1 235.88 54.31 225.04 33.54 390.27 356.73 0.25 1.44 
ESEL 13.95 4.95 12.82 5.29 26.26 20.97 0.51 -0.39 
IL2 1.19 0.88 0.9 0.9 6.07 5.17 4.02 17.11 
IL10 0.49 0.41 0.37 0.37 3.75 3.38 5.73 39.33 
TNFa 0.78 0.26 0.6 0.59 1.48 0.89 1.17 0.05 
IL1a 0.25 0.23 0.19 0.19 2.18 1.99 6.45 48.23 
hs-CRP 2.24 3.32 1.1 0.1 18.3 18.2 2.91 8.89 
Transit Time 228.31 76.07 232.5 66 428 362 0.38 -0.04 
FC 43 48.1 25.95 10 316 306 3.25 12.69 
IL6 0.93 1.34 0.55 0.18 8.59 8.41 4.01 16.93 
IL8 53.22 122.81 3.99 0.8 415 414.2 2.39 4.08 
IL1b 1.27 3.17 0.68 0.26 31.09 30.83 8.5 76.64 
IL1RA 301.11 343.85 153.15 24.3 1657.37 1633.07 2.31 5 
VEGF 60.4 48.83 46.2 8.57 283.08 274.51 2.19 5.81 
EGF 56.01 38.53 49.36 2.72 228.15 225.43 1.62 4.56 
MCP1 94.07 105.47 71.19 4.21 646 641.79 4.04 17.4 
PSEL 272.82 136.38 226.03 134.21 729.24 595.03 1.89 2.83 
LSEL 1852.8 323.24 1847.05 1242.69 2809.83 1567.14 0.52 0.1 
Abnormal 
mean sd median min max range skew kurtosis 
age 34.91 10.29 32.45 20.4 53.9 33.5 0.47 -1.05 
Genetic Risk Score 1.55 1.11 1.59 -1.25 3.75 5 -0.43 0.25 
Number CDFDR 1.38 0.64 1 1 3 2 1.31 0.47 
VCAM1 618.51 144.8 557.43 455.43 1034.17 578.74 1.05 0.36 
ICAM1 251.99 46.76 252.92 135.99 324.16 188.17 -0.42 -0.49 
ESEL 15.85 4.86 15.45 7.61 25.33 17.72 0.21 -1.09 
IL2 1.09 0.5 0.9 0.9 3.07 2.17 2.87 7.58 
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IL10 0.47 0.43 0.37 0.37 2.58 2.21 4.45 18.78 
TNFa 0.78 0.21 0.74 0.59 1.21 0.62 0.87 -0.47 
IL1a 0.28 0.17 0.19 0.19 0.92 0.73 2.37 5.48 
hs-CRP 3.64 3.57 2.3 0.2 11.7 11.5 1 -0.21 
Transit Time 236.27 87.47 225.5 89 474 385 1.1 1.58 
FC 165.02 201.66 78.65 10 866.5 856.5 2.03 3.68 
IL6 1.06 1.07 0.72 0.26 5.75 5.49 3.19 11.25 
IL8 104.01 150.76 9.32 1.53 415 413.47 1.23 -0.08 
IL1b 0.86 0.6 0.66 0.26 2.45 2.19 1.2 0.39 
IL1RA 398.19 297.99 332.86 49.72 1191.84 1142.12 1.21 0.53 
VEGF 59.37 36.85 52.88 14.95 167.43 152.48 1.16 1 
EGF 59.26 41.43 49.55 8.69 188.13 179.44 1.43 1.92 
MCP1 88.63 43.15 79.73 32.94 201.92 168.98 1.09 0.3 
PSEL 296.08 132.65 259.44 136.28 636.95 500.67 0.98 -0.14 
LSEL 1946.39 222.26 1947.27 1495.67 2316.14 820.47 -0.1 -1.11 
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Table S5. Multivariate logistic regression with stepwise selection 
 
 
Variable beta se z OR lower upper p 
        
Best fit AIC = 80.35; maximal model (all predictors) AIC = 93.65 
FC 0.04 0.01 3.58 1.04 1.02 1.07 3.46E-04 
Genetic Risk Score 2.42 0.75 3.21 11.22 3.25 68.41 1.35E-03 
hs-CRP 0.42 0.14 2.93 1.52 1.17 2.09 3.43E-03 
VEGF -0.06 0.02 -2.66 0.94 0.89 0.98 7.80E-03 
Smoking-Ex -4.46 1.73 -2.58 0.01 0.00 0.20 9.98E-03 
IL8 0.01 0.00 2.54 1.01 1.00 1.02 1.12E-02 
Family burden 3.28 1.32 2.49 26.67 2.84 594.97 1.26E-02 
PSEL 0.01 0.00 2.36 1.01 1.00 1.02 1.85E-02 
VCAM1 0.01 0.00 2.31 1.01 1.00 1.02 2.07E-02 
ESEL 0.21 0.10 2.12 1.23 1.03 1.54 3.43E-02 
age 0.11 0.05 1.94 1.11 1.01 1.26 5.22E-02 
ICAM1 -0.02 0.01 -1.87 0.98 0.96 1.00 6.21E-02 
Transit time 0.01 0.01 1.70 1.01 1.00 1.02 8.86E-02 
Smoking-Current 0.44 0.96 0.46 1.55 0.23 10.81 6.47E-01 
        
Best fit BIC = 101.95; maximal model (all predictors) BIC = 161.34 
FC 0.01 0.00 3.57 1.01 1.01 1.02 3.63E-04 
Family burden 2.22 0.73 3.04 9.24 2.29 42.65 2.37E-03 
Genetic Risk Score 1.02 0.35 2.89 2.78 1.47 6.02 3.89E-03 
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Table S6. Confusion matrices and prediction evaluation metrics 
 
 
Elastic net Random forest 
  
Confusion Matrix and Statistics Confusion Matrix and Statistics 
  
Reference Reference 
Prediction  normal abnormal Prediction  normal abnormal 
normal        22 2 normal        23 1 
abnormal      11 6 abnormal      10 1 
                                                                                      
Accuracy:  0.6829           Accuracy:  0.7317           
95% CI:  (0.5191, 0.8192) 95% CI:  (0.5706, 0.8578) 
No Information Rate:  0.8049           No Information Rate:  0.8049           
P-Value [Acc > NIR]:  0.9802           P-Value [Acc > NIR]:  0.91183          
                                                                                    
Kappa:  0.2922           Kappa:          0.4011 
 Mcnemar's Test P-Value:      0.0265     Mcnemar's Test P-Value:         0.01586 
                                                                                    
Sensitivity:     0.7500      Sensitivity:  0.8750           
Specificity:  0.6667           Specificity:  0.6970           
Pos Pred Value:  0.3529           Pos Pred Value:  0.4118           
Neg Pred Value:  0.9167           Neg Pred Value:  0.9583           
Prevalence:   0.1951        Prevalence:  0.1951           
Detection Rate:    0.1463       Detection Rate:  0.1707           
Detection Prevalence:  0.4146           Detection Prevalence:  0.4146           
Balanced Accuracy:  0.7083   Balanced Accuracy:  0.7860 
                                                                                      
  
Area under the curve:  0.7992 Area under the curve:  0.8712 
95% CI:  0.6191-0.9794 95% CI: 0.7465-0.9959 
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Table S7. Predictor importance 
 
 Random forest  Elastic net 
 
Importance Importance 
1 
FC 9.67E-02 familyBurden 0.26636 
2 
geneticRiskScore 2.64E-02 geneticRiskScore 0.13037 
3 hs-CRP 1.51E-02 FC 0.04367 
4 IL6 4.31E-03 
5 familyBurden 2.26E-03 
6 
SmokingEx 4.38E-05 
7 
SexM -1.59E-04 
8 
ESEL -1.72E-04 
9 smokingCurrent -2.68E-04 
10 EGF -3.54E-04 
11 TNFa -5.21E-04 
12 
VCAM1 -5.94E-04 
13 
IL1b -9.66E-04 
14 
IL1RA -1.02E-03 
15 transitTime -1.08E-03 
16 LSEL -1.14E-03 
17 IL2 -1.29E-03 
18 
VEGF -1.32E-03 
19 
ICAM1 -1.67E-03 
20 
IL8 -1.72E-03 
 Note. Top 20/23 predictors shown for the random forest. Random forest importance = permutation decrease in 
accuracy; elastic net importance = | t-statistic | 
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Figure S1. FDR relative risk compared to baseline population risk 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
 
Figure S2. Participant flow through the study 
  
 
Note: FDR – first degree relative; VCE – video capsule endoscopy  
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Figure S3. Faecal calprotectin levels in FDR individual with observed normal or abnormal Lewis score, where Lewis 
score >=790 = abnormal. Red dotted line = faecal calprotectin of 50 ug/g. 
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Figure S4. Correlation among continuous predictors for 124 individuals with complete data (67 high RR, 57 low RR). 
age = age in years; geneticRiskScore = weighted sum of risk SNPs;  familyBurden = number of family members with 
Crohn's disease;  transitTime = length of time capsule endoscopy capsule is in the gastrointestinal tract;  IL2, IL10, 
IL1b, IL1a, IL6, IL8 = interleukin–2, –10, –1b, –1a, –6, –8;  VCAM1, ICAM1 = vascular adhesion molecule, intercellular 
adhesion molecule;  ESEL, LSEL, PSEL = E–, L–, P–selectin;  EGF, VEGF = endothelial growth factor, vascular endothelial 
growth factor;  TNFa = tumor necrosis factor alpha;  MCP1 = Monocyte chemoattractant protein 1;  FC = faecal 
calprotectin;  CRP = C-reactive protein 
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Figure S5. Plot showing correlation (r = 0.72) between the updated risk score
10
 for 69 SNPs (plus NOD2 and smoking) 
versus risk scores based on all 134 CD associated SNPs available in our study. 
